Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
ArriVent goes Further into PACC mutations
The group is aiming for accelerated approval with the upcoming Alpacca trial.
Nuvalent loses ground in the front line
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
Lunsumio steps into Columvi territory
Sunmo succeeds in a setting very similar to Starglo's.
Exelixis claims a next-generation colorectal win
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
After Blueprint's takeover comes Cogent's big test
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
Opinion: dealing with failure, iTeos style
When your investment case breaks down, why not just do the decent thing?
Arvinas and 3SBio hope to do better
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
DLL3 goes trispecific
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
